Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Pulmonology Reports
Published in: Current Pulmonology Reports 3/2020

01-09-2020 | Insomnia | Sleeping and Breathing (A Abreu, Section Editor)

Management of Insomnia in Chronic Lung Diseases

Authors: Kori Ascher, Alexandre R. Abreu, Alejandro D. Chediak

Published in: Current Pulmonology Reports | Issue 3/2020

Login to get access

Abstract

Purpose of Review

Review the treatment of insomnia in those with chronic lung diseases.

Recent Findings

Cognitive behavioral therapy for insomnia and positive airway pressure, the latter for those with sleep disordered breathing, are effective and safe alternatives to hypnotic therapy. Some new hypnotics improve sleep via mechanisms that theoretically render them safe to use in those afflicted with both insomnia and chronic lung disease.

Summary

Treatment for insomnia may include cognitive behavioral therapy, positive airway pressure, and pharmacotherapy. Computerized cognitive behavioral therapy is a safe and effective treatment alternative for insomnia. Insomnia comorbid with obstructive sleep apnea can respond favorably to positive airway pressure therapy. Prescription hypnotics that affect sleep via modulation of melatonin, histamine, and orexin pathways are theoretically well suited for treatment of insomnia in those with chronic lung diseases. We offer the reader an algorithm to manage a patient with insomnia and chronic lung disease.
Literature
1.
Dodge R, Cline MG, Quan SF. The natural history of insomnia and its relationship to respiratory symptoms. Arch Intern Med. 1995;155(16):1797–800.PubMedCrossRef
2.
3.
4.
Bonnet MH, Arand DL. Hyperarousal and insomnia: state of the science. Sleep Med Rev. 2010;14(1):9–15.PubMedCrossRef
5.
Grima NA, Bei B, Mansfield D. Insomnia theory and assessment. Aust J Gen Pract. 2019;48(4):193–7.PubMedCrossRef
6.
Budhiraja R, Siddiqi TA, Quan SF. Sleep disorders in chronic obstructive pulmonary disease: etiology, impact, and management. J Clin Sleep Med. 2015;11(3):259–70.PubMedPubMedCentralCrossRef
7.
Batal O, Khatib OF, Bair N, Aboussouan LS, Minai OA. Sleep quality, depression, and quality of life in patients with pulmonary hypertension. Lung. 2011;189(2):141–9.PubMedCrossRef
8.
Tomaszek L, Cepuch G, Pawlik L. Evaluation of selected insomnia predictors in adolescents and young adults with cystic fibrosis. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2018;162(3):212–8.PubMedCrossRef
9.
•• Seda G, Tsai S, Lee-Chiong T. Medication effects on sleep and breathing. Clin Chest Med. 2014;35(3):557–69 This paper reports the normal physiological changes in repiration during sleep and the impact of select medications on repirations during sleep.PubMedCrossRef
10.
Genta PR, Eckert DJ, Gregorio MG, et al. Critical closing pressure during midazolam-induced sleep. J Appl Physiol (1985). 2011;111(5):1315–22.CrossRef
11.
Coyle MA, Mendelson WB, Derchak PA, James SP, Wilson MG. Ventilatory safety of zaleplon during sleep in patients with obstructive sleep apnea on continuous positive airway pressure. J Clin Sleep Med. 2005;1(1):97.PubMedCrossRef
12.
Rosenberg R, Roach JM, Scharf M, Amato DA. A pilot study evaluating acute use of eszopiclone in patients with mild to moderate obstructive sleep apnea syndrome. Sleep Med. 2007;8(5):464–70.PubMedCrossRef
13.
Kryger M, Roth T, Wang-Weigand S, Zhang J. The effects of ramelteon on respiration during sleep in subjects with moderate to severe chronic obstructive pulmonary disease. Sleep Breath. 2009;13(1):79–84.PubMedCrossRef
14.
Herring WJ, Snyder E, Budd K, Hutzelmann J, Snavely D, Liu K, et al. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Neurology. 2012;79(23):2265–74.PubMedCrossRef
15.
Michelson D, Snyder E, Paradis E, Chengan-Liu M, Snavely DB, Hutzelmann J, et al. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014;13(5):461–71.PubMedCrossRef
16.
Sun H, Palcza J, Rosenberg R, Kryger M, Siringhaus T, Rowe J, et al. Effects of suvorexant, an orexin receptor antagonist, on breathing during sleep in patients with chronic obstructive pulmonary disease. Respir Med. 2015;109(3):416–26.PubMedCrossRef
17.
Douglas NJ, White DP, Weil JV, et al. Hypoxic ventilatory response decreases during sleep in normal men. Am Rev Respir Dis. 1982;125(3):286–9.PubMed
18.
Douglas NJ, White DP, Weil JV, Pickett CK, Zwillich CW. Hypercapnic ventilatory response in sleeping adults. Am Rev Respir Dis. 1982;126(5):758–62.PubMed
19.
20.
Smith DRL-C Jr, T. Respiratory physiology during sleep. Sleep Med Clin. 2008;3:497–502.CrossRef
21.
Gothe B, Altose MD, Goldman MD, Cherniack NS. Effect of quiet sleep on resting and CO2-stimulated breathing in humans. J Appl Physiol Respir Environ Exerc Physiol. 1981;50(4):724–30.PubMed
22.
23.
24.
Krachman SL, Criner GJ, Chatila W. Cor pulmonale and sleep-disordered breathing in patients with restrictive lung disease and neuromuscular disorders. Semin Respir Crit Care Med. 2003;24(3):297–306.PubMedCrossRef
25.
26.
van Manen JG, Bindels PJ, IJzermans CJ, van der Zee JS, Bottema BJ, Schade E. Prevalence of comorbidity in patients with a chronic airway obstruction and controls over the age of 40. J Clin Epidemiol. 2001;54(3):287–93.PubMedCrossRef
27.
•• Mason M, Cates CJ, Smith I. Effects of opioid, hypnotic and sedating medications on sleep-disordered breathing in adults with obstructive sleep apnoea. Cochrane Database Syst Rev. 2015;7:CD011090 This review paper summarizes 14 different studies involving patients with OSA comparing placebo to either hypnotics, sedatives, or opioids.
28.
Zinchuk AV, Gentry MJ, Concato J, Yaggi HK. Phenotypes in obstructive sleep apnea: a definition, examples and evolution of approaches. Sleep Med Rev. 2017;35:113–23.PubMedCrossRef
29.
Stege G, Vos PJ, van den Elshout FJ, Richard Dekhuijzen PN, van de Ven MJ, Heijdra YF. Sleep, hypnotics and chronic obstructive pulmonary disease. Respir Med. 2008;102(6):801–14.PubMedCrossRef
30.
Kryger M, Wang-Weigand S, Zhang J, Roth T. Effect of ramelteon, a selective MT(1)/MT (2)-receptor agonist, on respiration during sleep in mild to moderate COPD. Sleep Breath. 2008;12(3):243–50.PubMedCrossRef
31.
Cohn MA. Effects of zolpidem, codeine phosphate and placebo on respiration. A double-blind, crossover study in volunteers. Drug Saf. 1993;9(4):312–9.PubMedCrossRef
32.
Cummiskey J, Guilleminault C, Del Rio G, Silvestri R. The effects of flurazepam on sleep studies in patients with chronic obstructive pulmonary disease. Chest. 1983;84(2):143–7.PubMed
33.
34.
Gatti RC, Burke PR, Otuyama LJ, Almeida DR, Tufik S, Poyares D. Effects of zolpidem CR on sleep and nocturnal ventilation in patients with heart failure. Sleep. 2016;39(8):1501–5.PubMedPubMedCentralCrossRef
35.
36.
Light RW, Merrill EJ, Despars J, Gordon GH, Mutalipassi LR. Doxepin treatment of depressed patients with chronic obstructive pulmonary disease. Arch Intern Med. 1986;146(7):1377–80.PubMedCrossRef
37.
Trauer JM, Qian MY, Doyle JS, Rajaratnam SM, Cunnington D. Cognitive behavioral therapy for chronic insomnia: a systematic review and meta-analysis. Ann Intern Med. 2015;163(3):191–204.PubMedCrossRef
38.
•• Zachariae R, Lyby MS, Ritterband LM, O’Toole MS. Efficacy of internet-delivered cognitive-behavioral therapy for insomnia - a systematic review and meta-analysis of randomized controlled trials. Sleep Med Rev. 2016;30:1–10 This meta anaylsis serves as evidence to support the use of computerized CBT-I across several patient populations.PubMedCrossRef
39.
Ye L, Pien GW, Ratcliffe SJ, Björnsdottir E, Arnardottir ES, Pack AI, et al. The different clinical faces of obstructive sleep apnoea: a cluster analysis. Eur Respir J. 2014;44(6):1600–7.PubMedPubMedCentralCrossRef
40.
Bjornsdottir E, Janson C, Sigurdsson JF, et al. Symptoms of insomnia among patients with obstructive sleep apnea before and after two years of positive airway pressure treatment. Sleep. 2013;36(12):1901–9.PubMedPubMedCentralCrossRef
41.
•• Nguyen XL, Rakotonanahary D, Chaskalovic J, Fleury B. Insomnia related to sleep apnoea: effect of long-term auto-adjusting positive airway pressure treatment. Eur Respir J. 2013;41(3):593–600 This manuscript describes the relationship of sleep apnea to insomnia and the effect of positive pressure therapy on insomnia.PubMedCrossRef
Metadata
Title
Management of Insomnia in Chronic Lung Diseases
Authors
Kori Ascher
Alexandre R. Abreu
Alejandro D. Chediak
Publication date
01-09-2020
Publisher
Springer US
Published in
Current Pulmonology Reports / Issue 3/2020
Electronic ISSN: 2199-2428
DOI
https://doi.org/10.1007/s13665-020-00253-z

Other articles of this Issue 3/2020

Current Pulmonology Reports 3/2020 Go to the issue

Sleeping and Breathing (A Abreu, Section Editor)

Cannabinoids and Sleep: Helpful or Harmful?

Environmental and Occupational Health (S Cherian, Section Editor)

Imaging in Occupational and Environmental Lung Disease

Sleeping and Breathing (A Abreu, Section Editor)

Sleep, Obstructive Sleep Apnea, and Chronic Alveolar Hypoventilation in Cystic Fibrosis: Role of Noninvasive Ventilation During Sleep

Pulmonary Radiology (M Stephens and S Kapur, Section Editors)

Intrathoracic Manifestations of Sarcoidosis: an Imaging Review Highlighting Atypical Features

Pulmonary Radiology (M Stephens and S Kapur, Section Editors)

Current Applications for Nuclear Medicine Imaging in Pulmonary Disease

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits